|
Clinical Question:
Do Long-acting natriuretic peptide, vessel dilator, kaliuretic peptide and
atrial natriuretic peptide have significant anticancer effects in prostate
adenocarcinoma cells?
Bottom Line:
Results indicate that these peptide hormones' anticancer effects are
specific. Furthermore, they have very potent effects of eliminating up to
97% of prostate cancer cells within 24 h of treatment.
Reference:
Four peptide hormones' specific decrease (up to 97%) of human prostate
carcinoma cells.Vesely BA, Alli AA, Song SJ, Gower WR Jr, Sanchez-Ramos J,
Vesely DL. Eur J Clin Invest. 2005 Nov;35(11):700-10.
Synopsis:
Mortality from prostate cancer remains a significant problem with current
treatment(s), with an expected 30 350 deaths from prostate cancer in 2005.
Long-acting natriuretic peptide, vessel dilator, kaliuretic peptide and
atrial natriuretic peptide have significant anticancer effects in breast and
pancreatic adenocarcinomas. Whether these effects are specific and whether
they have anticancer effects in prostate adenocarcinoma cells has not been
determined.These peptide hormones were evaluated to determine if they have
specific anticancer effects in human prostate adenocarcinomas. Dose-response
curves revealed a significant (P < 0.05) decrease in human prostate cancer
number with each tenfold increase in the concentration from 1 microM to 1000
microM (i.e. 1 mM) of these four peptide hormones. There was a 97.4%, 87%,
88% and 89% (P < 0.001 for each) decrease in prostate cancer cells secondary
to vessel dilator, long-acting natriuretic peptide, kaliuretic peptide and
atrial natriuretic peptide, respectively, at their 1-mM concentrations
within 24 h, without any proliferation in the 3 days following this
decrease. These same hormones decreased DNA synthesis from 68% to 89% (P <
0.001). When utilized with their respective antibodies their ability to
decrease prostate adenocarcinoma cells or inhibit their DNA synthesis was
completely blocked. Western blots revealed that for the first time
natriuretic peptide receptors (NPR) A- and C- were present in prostate
cancer cells. |